SAN FRANCISCO, Feb. 27, 2017 /PRNewswire/ -- Fluxion Biosciences announced today that Genetracer Biotech of Santander,
Liquid biopsies offer the potential to improve treatment of cancer by providing an affordable, non-invasive diagnostic. Fluxion's technologies include the IsoFlux system for high-sensitivity detection of cancer cells from a routine blood draw, and the Spotlight 59 NGS Oncology Panel for ultra-sensitive mutation detection of CTCs and ctDNA (circulating tumor DNA) isolated from routine blood samples. These solutions allow testing for a broad range of cancer biomarkers that will help guide treatment decisions using an emerging class of precision cancer therapies.
As a Certified Service Provider, Genetracer Biotech will provide liquid biopsy services supporting cancer research centers and bio-pharmaceutical companies. Additionally, Genetracer will participate in Fluxion's upcoming liquid biopsy lung cancer clinical study. The study is aimed at improving lung cancer diagnostics by providing early stratification of high risk patients.
"We are delighted to partner with Genetracer Biotech," said Dr. Cristian Ionescu-Zanetti, Fluxion's CTO. "Genetracer is a leader in the development of tests for precision medicine, and we are honored to be working with them. We look forward to pioneering new liquid biopsy tests with Genetracer that lead to dramatically improved patient outcomes."
About Fluxion BiosciencesFluxion's pioneering liquid biopsy technologies include the IsoFlux CTC Liquid Biopsy System and the Spotlight 59 NGS Oncology Panel for ultra-sensitive mutation detection from CTCs and ctDNA. Fluxion's technologies are used globally by leading cancer centers developing new tests for early cancer detection and patient monitoring. For more information about Fluxion Biosciences' liquid biopsy capabilities, visit http://isoflux.fluxionbio.com.
About Genetracer BiotechGenetracer Biotech is a European SME pioneering in Liquid Biopsy and Next Generation Sequencing (NGS). DECODER (http://decodergentest.com/en/#) is the first noninvasive blood test that delivers high quality enrichment of CTCs and ctDNA using the advantages of the IsoFlux CTC Liquid Biopsy System and NGS. The ability to detect and quantify tumor mutations has proven effective in tracking tumor dynamics in real time. DECODER may influence clinical outcome and help to understand the dynamics of cancer evolution. With Decoder by Genetracer be a step ahead.
Fluxion BiosciencesJeff Jensenemail: [email protected]+1 650-241-4777
Genetracer BiotechEdificio IBBTEC, en el Parque Científico Tecnológico de Cantabriac/ Albert Einstein 22 – 39011 Santander. Spain.TEL. +34 942 266 318email: [email protected]
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/fluxion-biosciences-appoints-genetracer-biotech-of-spain-as-an-isoflux-liquid-biopsy-certified-service-provider-300413404.html
SOURCE Fluxion Biosciences Inc.
Subscribe to our Free Newsletters!
Leukoplakia refers to a painless, raised white patch in the mouth that does not go away on rubbing, ...
Health insurance has emerged one of the fastest growing segments in the non-life insurance industry ...
Strabismus or squint is a failure of the two eyes to maintain proper alignment when looking at an ...View All